Clinical Trial

A Study of Suizenji in Patients With Unresectable Pancreatic Cancer

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of standard chemotherapy with or without a novel High Intensity Focused Ultrasound system (Code: Suizenji) in patients with unresectable pancreatic cancer who are refractory or intolerant to first-line chemotherapy.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-10-27; most recent amendment 2026-03-12.
Status change: Recruiting → Active, Not Recruiting 2026-03-12
Status change: Not Yet Recruiting → Recruiting 2023-01-31
Trial Details
NCT Number NCT05601323
Lead Sponsor SONIRE Therapeutics Inc.
Conditions Unresectable Pancreatic Cancer
Enrollment 90 participants
Start Date 2023-01-31
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-16